BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.

Employees

728

Sector

Pharmaceuticals

Calendar

07-30 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
15/07/25	47.35 $	-0.71%	824,967
14/07/25	47.69 $	+2.63%	3,861,152
11/07/25	46.47 $	+0.43%	2,187,986
10/07/25	46.27 $	+0.63%	2,424,941
09/07/25	45.98 $	+6.46%	4,634,012

Delayed Quote Nasdaq, July 15, 2025 at 04:35 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

47.69USD

Average target price

61.29USD

Spread / Average Target

+28.51%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 17:52:31 15/07/2025 BST			5-day change	1st Jan Change
47.42 ^USD	-0.58%		+9.78%	+72.80%

07-11	BridgeBio Pharma, Inc. - Special Call
07-09	BridgeBio Pharma May Keep Outperforming as Attruby Sales Beat Consensus, Oppenheimer Says	MT

Capitalization	9.06B 7.75B 7.22B 6.73B 12.39B 779B 13.81B 86.97B 32.97B 364B 33.96B 33.26B 1,336B	P/E ratio 2025 *	-16.4x	P/E ratio 2026 *	-23x
Enterprise value	10.35B 8.86B 8.25B 7.69B 14.16B 890B 15.78B 99.39B 37.68B 416B 38.81B 38.01B 1,527B	EV / Sales 2025 *	22.7x	EV / Sales 2026 *	13.8x
Free-Float	78.66%	Yield 2025 *	-	Yield 2026 *	-

BridgeBio Pharma, Inc. - Special Call	07-11
BridgeBio Pharma May Keep Outperforming as Attruby Sales Beat Consensus, Oppenheimer Says	07-09	MT
Oppenheimer Upgrades BridgeBio Pharma to Outperform From Market Perform, Price Target is $60	07-09	MT
BridgeBio Pharma, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08:40 AM	07-03
BridgeBio Pharma Sells Part of Beyonttra Royalty Rights for $300 Million	06-30	MT
BridgeBio Pharma, Inc.(NasdaqGS:BBIO) dropped from Russell 3000E Value Index	06-30	CI
BridgeBio Pharma, Inc.(NasdaqGS:BBIO) dropped from Russell 3000 Value Index	06-30	CI
BridgeBio Pharma, Inc.(NasdaqGS:BBIO) dropped from Russell 2500 Value Index	06-30	CI
BridgeBio Pharma, Inc.(NasdaqGS:BBIO) dropped from Russell Small Cap Comp Value Index	06-30	CI
BridgeBio Pharma, Inc.(NasdaqGS:BBIO) dropped from Russell 2000 Value Index	06-30	CI
BridgeBio Pharma, Inc.(NasdaqGS:BBIO) dropped from Russell Small Cap Comp Value Benchmark	06-29	CI
BridgeBio Pharma, Inc.(NasdaqGS:BBIO) dropped from Russell 3000E Value Benchmark	06-29	CI
BridgeBio Pharma, Inc.(NasdaqGS:BBIO) dropped from Russell 3000 Value Benchmark	06-29	CI

Oppenheimer Upgrades BridgeBio Pharma to Outperform From Market Perform, Price Target is $60	07-09	MT
Wolfe Research Initiates Coverage on BridgeBio Pharma With Outperform Rating, $49 Price Target	06-17	MT
Mizuho Adjusts Price Target on BridgeBio Pharma to $60 From $53, Maintains Outperform Rating	05-05	MT
UBS Adjusts Price Target on BridgeBio Pharma to $72 From $65, Maintains Buy Rating	04-30	MT
Redburn Atlantic Initiates BridgeBio Pharma at Buy With $50 Price Target	03-31	MT

BridgeBio Pharma, Inc. Share Price

Equities

BBIO

US10806X1028

Pharmaceuticals

Valuation: BridgeBio Pharma, Inc.

Chart: BridgeBio Pharma, Inc.

Latest news: BridgeBio Pharma, Inc.

Last Transcript: BridgeBio Pharma, Inc.

Analysts' recommendations: BridgeBio Pharma, Inc.

Press Releases: BridgeBio Pharma, Inc.

News in other languages: BridgeBio Pharma, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: BridgeBio Pharma, Inc.

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

BridgeBio Pharma : BBIO – Encaleret – ADH1 – ENDO 2025 – Phase 2 Over 42 Months Data Results	07-14	PU
BridgeBio Pharma : BBIO – Encaleret – ADH1 – ENDO 2025 – Baseline Characteristics of Pediatric Participants in the CLARIFY Disease Monitoring Study	07-14	PU
BridgeBio Pharma : BBIO – Encaleret – ADH1 – ENDO 2025 – CALIBRATE-PEDS Phase 2/3 Study Design	07-13	PU
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty	06-30	GL
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET	06-26	GL

Bayer : le CHMP recommande l'approbation d'acoramidis	12-13
EU-Ausschuss empfiehlt Zulassung von neuem Bayer-Herzmedikament	12-13
AstraZeneca : essai positif dans l'amylose cardiaque	02/02/24
MÄRKTE USA/Hoffnung auf Ende der Fed-Zinserhöhungen stützt Aktien	17/07/23
Wall Street hoger gesloten	17/07/23

1 day	-0.29%
1 week	+9.42%
Current month	+9.45%
1 month	+14.88%
3 months	+38.03%
6 months	+35.03%
Current year	+72.23%

1 week	43.91	48.68
1 month	39.63	48.68
Current year	27.53	48.68
1 year	21.72	48.68
3 years	6.55	48.68
5 years	4.98	73.5
10 years	4.98	73.5

Manager	Title	Age	Since
Francis McCormick PRN	Corporate Officer/Principal	74	31/03/2019
Neil Kumar CEO	Chief Executive Officer	46	31/03/2015
Charles Homcy PRN	Corporate Officer/Principal	76	31/01/2019

Director	Title	Age	Since
Charles Homcy BRD	Director/Board Member	76	31/10/2018
Eric Aguiar BRD	Director/Board Member	63	28/02/2019
James Momtazee BRD	Director/Board Member	53	29/02/2016

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
BRIDGEBIO PHARMA, INC.	-0.14%	+9.42%	+69.76%	+425.70%	9.06B
CSL LIMITED	+3.75%	+1.08%	-18.25%	-15.37%	76.73B
REGENERON PHARMACEUTICALS, INC.	-2.68%	+1.16%	-48.79%	-8.80%	60.29B
SAMSUNG BIOLOGICS CO.,LTD.	-1.06%	+3.10%	+25.27%	+24.97%	53.68B
UCB	-1.07%	+0.35%	+18.67%	+104.43%	38.31B
BIOGEN INC.	-2.11%	-3.41%	-41.38%	-40.15%	19.5B
INNOVENT BIOLOGICS, INC.	+4.76%	+4.06%	+111.06%	+123.12%	17.86B
ALTEOGEN INC.	+5.39%	+12.47%	+72.11%	+768.52%	17.21B
INTRA-CELLULAR THERAPIES, INC.	-0.04%	-.--%	+68.78%	+135.69%	14.02B
INCYTE CORPORATION	-1.80%	+1.20%	+6.58%	-14.43%	13.55B
Average	+0.48%	+2.60%	+26.38%	+150.37%	32.02B
Weighted average by Cap.	+0.43%	+2.16%	+5.72%	+74.44%

	2025 *	2026 *
Net sales	456M 390M 363M 339M 623M 39.17B 695M 4.38B 1.66B 18.33B 1.71B 1.67B 67.21B	738M 631M 588M 548M 1.01B 63.42B 1.12B 7.08B 2.69B 29.67B 2.77B 2.71B 109B
Net income	-596M -510M -475M -443M -816M -51.28B -909M -5.73B -2.17B -23.99B -2.24B -2.19B -87.97B	-412M -352M -328M -306M -563M -35.39B -628M -3.95B -1.5B -16.56B -1.54B -1.51B -60.72B
Net Debt	1.29B 1.11B 1.03B 961M 1.77B 111B 1.97B 12.42B 4.71B 52.01B 4.85B 4.75B 191B	1.13B 970M 903M 843M 1.55B 97.44B 1.73B 10.88B 4.13B 45.59B 4.25B 4.16B 167B